Several brokerages have updated their recommendations and price targets on shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) in the last few weeks:

  • 10/24/2017 – Aurinia Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “
  • 10/23/2017 – Aurinia Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.00 price target on the stock.
  • 10/23/2017 – Aurinia Pharmaceuticals had its price target raised by analysts at Leerink Swann from $10.00 to $14.00. They now have an “outperform” rating on the stock.
  • 10/6/2017 – Aurinia Pharmaceuticals had its “buy” rating reaffirmed by analysts at Seaport Global Securities. They now have a $10.00 price target on the stock.
  • 9/19/2017 – Aurinia Pharmaceuticals was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $7.35 price target on the stock.
  • 9/13/2017 – Aurinia Pharmaceuticals was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $6.64 price target on the stock.
  • 9/6/2017 – Aurinia Pharmaceuticals was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $6.64 price target on the stock.
  • 8/31/2017 – Aurinia Pharmaceuticals was downgraded by analysts at Vetr from a “buy” rating to a “hold” rating. They now have a $6.64 price target on the stock.

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) opened at 5.75 on Wednesday. The company’s market capitalization is $480.04 million. Aurinia Pharmaceuticals Inc has a one year low of $2.02 and a one year high of $10.54. The company has a 50-day moving average price of $6.41 and a 200 day moving average price of $6.50.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.10. The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative return on equity of 28.61% and a negative net margin of 16,648.93%. Equities analysts anticipate that Aurinia Pharmaceuticals Inc will post ($1.01) EPS for the current year.

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.